We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertiv Holdings Co (VRT - Free Report) provides digital infrastructure and continuity solutions. There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. Moreover, VRT currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. VRT has been benefiting from strong order growth and backlog. The quarterly results reflected continued order momentum. Vertiv shares have surged 62.4% year to date (YTD), outperforming the broader Zacks Computer & Technology sector’s return of 22.1% and the Zacks IT Services industry’s gain of 2.4%. Vertiv’s improving liquidity makes the stock attractive.
Illumina Inc. (ILMN - Free Report) is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function.Illumina is successfully advancing its presence in the gene-sequencing market with competitive products and a strong pipeline. Its strategic initiatives and collaborations are boosting the NGS adoption, helping the company maintain leadership in research and clinical markets. Illumina’s growing oncology portfolio is driving advancements in cancer genomics, suggesting a long-term growth potential in this space. Moreover, the company now offers the full range of NovaSeq X products and also availed XLEAP-SBS chemistry to mid-throughput customers. Favorable solvency is also encouraging. Illumina Inc. reported second-quarter 2024 adjusted earnings per share (EPS) which beat the Zacks Consensus Estimate by a stupendous 200%. ILMN’s earnings beat estimates in each of the trailing four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Stock Picks for Week of August 26, 2024
Vertiv Holdings Co (VRT - Free Report) provides digital infrastructure and continuity solutions. There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. Moreover, VRT currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. VRT has been benefiting from strong order growth and backlog. The quarterly results reflected continued order momentum. Vertiv shares have surged 62.4% year to date (YTD), outperforming the broader Zacks Computer & Technology sector’s return of 22.1% and the Zacks IT Services industry’s gain of 2.4%. Vertiv’s improving liquidity makes the stock attractive.
Illumina Inc. (ILMN - Free Report) is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function.Illumina is successfully advancing its presence in the gene-sequencing market with competitive products and a strong pipeline. Its strategic initiatives and collaborations are boosting the NGS adoption, helping the company maintain leadership in research and clinical markets. Illumina’s growing oncology portfolio is driving advancements in cancer genomics, suggesting a long-term growth potential in this space. Moreover, the company now offers the full range of NovaSeq X products and also availed XLEAP-SBS chemistry to mid-throughput customers. Favorable solvency is also encouraging. Illumina Inc. reported second-quarter 2024 adjusted earnings per share (EPS) which beat the Zacks Consensus Estimate by a stupendous 200%. ILMN’s earnings beat estimates in each of the trailing four quarters.